GlassScriptPhysician profile
Michael Thomas Doldan
NPI 1457686347
$1,666.33
in general payments reported to CMS, 2019-2025
26 companies · $1,224 in 2025
The $1,224 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.49 · 2020: $22.83 · 2024: $391 · 2025: $1,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,615.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $229.38 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Phathom Pharmaceuticals, INC. | $134.90 | 2025 | Voquezna |
| Astellas Pharma US INC | $124.89 | 2024 | Veozah |
| Lilly USA, LLC | $124.35 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $118.21 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $112.91 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $104.67 | 2024-2025 | Rexulti |
| Abbvie INC. | $93.28 | 2025 | |
| Novo Nordisk INC | $88.22 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.94 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $56.31 | 2025 | Auvelity |
| Pfizer INC. | $55.42 | 2024-2025 | |
| Abbott Laboratories | $48.77 | 2020-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $41.42 | 2024-2025 | |
| Amgen INC. | $38.18 | 2025 | Evenity, Prolia, Repatha |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $33.00 | 2025 | Korlym |
| Genentech USA, INC. | $28.49 | 2019 | |
| Edwards Lifesciences Corporation | $22.12 | 2025 | Sapien 3 Ultra Resilia |
| Amneal Pharmaceuticals LLC | $21.37 | 2025 | Unithroid |
| Lundbeck LLC | $19.62 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $19.54 | 2025 | |
| Merck Sharp & Dohme LLC | $18.18 | 2025 | Gardasil 9, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.06 | 2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.28 | 2025 | Jardiance |
| Insulet Corporation | $16.00 | 2024 | Omnipod |
| Dexcom, INC. | $13.82 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Doldan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.